Join
Live feed
·
PRReleasevia Quantisnow
ImmunityBio Inc. logo

ImmunityBio Announces Approval in Macau SAR, China for ANKTIVA® in BCG-Unresponsive NMIBC with CIS ± Papillary Tumors

ByQuantisnow·Wall Street's wire, on your screen.
IBRX· ImmunityBio Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track IBRX (ImmunityBio Inc.) and more on Quantisnow.